(Q40484013)

20 September 2017

Amphotericin-B-mediated reactivation of latent HIV-1 infection (English)

1 reference

20 September 2017

0 references

Jones J

1

1 reference

20 September 2017

Kosloff BR

2

1 reference

20 September 2017

Benveniste EN

3

1 reference

20 September 2017

Shaw GM

4

1 reference

20 September 2017

Kutsch O

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

20 September 2017

1 reference

20 September 2017

331

1 reference

20 September 2017

1

1 reference

20 September 2017

106-116

1 reference

Signalling to translational activation of tumour necrosis factor-alpha expression in human THP-1 cells

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

MS-8209, a new Amphotericin B derivative that inhibits HIV-1 replication in vitro and restores T-cell activation via the CD3/TcR in HIV-infected CD4+ cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Amphotericin B induces tumor necrosis factor production by murine macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Re-emergence of HIV after stopping therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Relationship between viral load in blood, cerebrospinal fluid, brain tissue and isolated microglia with neurological disease in macaques infected with different strains of SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Rational design of drugs that induce human immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Derivatives of amphotericin inhibit infection with human immunodeficiency virus in vitro by different modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Effects of prostratin on T-cell activation and human immunodeficiency virus latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

CD154-CD40-induced reactivation of latent HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

HIV-1 in human alveolar macrophages from infected patients is latent in vivo but replicates after in vitro stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Antifungal use in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Macrophages as a source of HIV during opportunistic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

In vitro anti-HIV activity of sulfated amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Anti-HIV-1 activity of sulfated amphotericin B in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Inhibition of HIV replication by liposomal encapsulated amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Anti-viral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Histone acetyltransferases regulate HIV-1 enhancer activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Reservoirs for HIV infection and their persistence in the face of undetectable viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

New Evidence for the Existence of Long Lived Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Reduction of human immunodeficiency virus production and cytopathic effects by inhibitors of the Na+/K+/2Cl- cotransporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

7 January 2021

Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

7 January 2021

Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

7 January 2021

Alteration of intracellular potassium and sodium concentrations correlates with induction of cytopathic effects by human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.013

7 January 2021

10.1016/J.VIROL.2004.10.013

Identifiers

DOI

1 reference

20 September 2017

1 reference